Alpha Cognition Announces Publication of U.S. Patent Application for Benzgalantamine for Treating Persistent Post-Concussion Symptoms
Key Highlights
- ➤Patent application published for benzgalantamine treating persistent post-concussion symptoms
- ➤Pending claims cover persistent symptoms after mild traumatic brain injury
- ➤Application includes multiple administration routes and preclinical traumatic-brain-injury data
- ➤Publication expands Alpha Cognition’s intellectual property beyond Alzheimer’s disease
Expert Statements
Michael McFadden, Chief Executive Officer of Alpha Cognition
“Publication of this application represents another step in building intellectual property around the potential therapeutic breadth of benzgalantamine”
Michael McFadden, Chief Executive Officer of Alpha Cognition
“Persistent post-concussion symptoms can include cognitive, physical, sleep, and behavioral impairments that may continue well beyond the initial injury.”
Michael McFadden, Chief Executive Officer of Alpha Cognition
“There are currently no FDA-approved pharmacologic treatments specifically indicated for persistent post-concussion symptoms, underscoring the need for new therapeutic approaches.”
Alpha Cognition Announces Publication of U.S. Patent Application for Benzgalantamine for Treating Persistent Post-Concussion Symptoms
Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing and commercializing novel therapeutics for debilitating neurodegenerative disorders, today announced that the United States Patent and Trademark Office (USPTO) published U.S. Patent No. 20260325541-A1, titled “Benzgalantamine for Treating Persistent Post-Concussion Symptoms.”
Get started
Create a free account to read the full story.
